Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Revance Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1]. Summary by Sections Allegations - The complaint alleges that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach subjected the company to increased risks of litigation, monetary, and reputational harm [1]. - The allegations suggest that these issues increased the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the lawsuit is from February 29, 2024, to December 6, 2024 [1]. - Shareholders are encouraged to register for the class action by March 4, 2025, to potentially be appointed as lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

BENSALEM, Pa., Jan. 15, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REVANCE THERAPEUTICS, INC. (RVNC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MARCH 4, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the ...

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and Dec ...

JOHNSON CITY, Tenn., Jan. 13, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of Revance Therapeutics, Inc., ("Revance") (Nasdaq: RVNC), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("Shares") of Revance, at a price of $3.10 per Share in cash, without interest and less any applicable tax w ...

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=122002&from=4 CLASS PERIOD ...

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors who purchased Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company. [CONTACT FORM] The lawsuit was filed on behalf of investors who acquired Revance ...

Class Action Lawsuit Details - The lawsuit seeks to recover losses for Revance investors affected by alleged securities fraud between February 29, 2024, and December 6, 2024 [1] - Investors have until March 4, 2025, to request appointment as lead plaintiff [3] Allegations Against Revance - Revance allegedly breached the Distribution Agreement with Teoxane, which granted exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [2] - The breach increased the risk of litigation, monetary harm, reputational damage, and potential delays or amendments to the tender offer [2] - Revance's public statements during this period are alleged to have been materially false and misleading [2] Legal Representation - Levi & Korsinsky, LLP has secured hundreds of millions of dollars for aggrieved shareholders over the past 20 years [4] - The firm has been ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4] - Levi & Korsinsky employs over 70 professionals and specializes in complex securities litigation [4]

LOS ANGELES, Jan. 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 29, 2024 and December 6, 2024, inclusive (the "Class ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=121491&from=4CLASS PERIOD: ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) in the United States District Court for the Middle District of Tennessee on behalf of all persons and entities who purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the “Class Period”) ...